Project Grant R01CA316401
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $547K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
France
Similar Awards
- The National Institutes of Health National Cancer Institute awarded the University of Virginia $730,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify N6-methyladenosine (M6A) marks and genes influencing lung cancer risk. The award funds a five-year project (August 1, 2026 through July 31, 2031) combining genetic epidemiology, multi-omics analysis, and in vitro studies to characterize M6A's role in lung tumorigenesis. The work includes conducting an...
- The National Cancer Institute awarded The Leland Stanford Junior University $635,340 on May 4, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct functional genomic dissection of lung cancer in vivo. Stanford will integrate genetically engineered mouse models, multiplexed CRISPR-based genome editing, and tumor barcoding to assess tumor suppressor gene function across multiple genotypes and their effects on lung tumor initiation and growth in parallel. In Aim 1,...
- The National Cancer Institute awarded the Institute For Systems Biology $555,592 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop AI-driven infrastructure for integrating and analyzing cancer datasets and identifying cancer risk factors. The recipient will construct a multi-modal, harmonized resource for the tumor microenvironment featuring an AI-powered spatial search tool. Using spatial datasets from the Human Tumor Atlas Network (HTAN), the...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded The Leland Stanford Junior University $626,743 on July 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop intraoperative molecular imaging of lung cancer using panitumumab-IRDYE800 (PAN800). The funded research addresses accurate tumor localization during lung cancer surgery, particularly for small, less dense, or deep tumors and minimally invasive surgical approaches where palpation is difficult. Current techniques...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $532,627 for research on tumor suppressive functions of SMARCA4 in lung cancer, effective September 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds a five-year project (through August 31, 2031) conducted at Columbia's Health Sciences Division in New York, New York. The research develops and employs genetically engineered mouse models of SMARCA4-deficient lung...